Jill O’Donnell-Tormey, Ph.D., is chief executive officer and director of scientific affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 that is today the global leader in supporting and coordinating research aimed at harnessing the immune system’s power to conquer all cancers. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University.
In 2020, Dr. O'Donnell-Tormey was awarded the 2020 Public Service Award from the Society for Immunotherapy of Cancer (SITC) for her work as a true leader and strong advocate for cancer immunotherapy through her continuous service at the Cancer Research Institute (CRI).
Immunotherapy is here to stay. It's not just a blip, it's not overhyped — I think it is going to become the standard of care for many cancer types.
Dr. O’Donnell-Tormey serves on the boards of HemaCare, The City University of New York (CUNY), Richmond University Medical Center, and the Staten Island Foundation. In 1998, she was named one of Irish America magazine’s "Top 100 Irish Americans," and in 2002, she received the Fairleigh Dickinson University Pinnacle Award—the highest honor bestowed on its alumni. In 2013, Dr. O’Donnell-Tormey received the Cancer Research Institute’s Frederick W. Alt Award for New Discoveries in Immunology, which the Institute awards to formerly-funded postdoctoral fellows who make significant contributions to immunology research.
Dr. O’Donnell-Tormey holds a Bachelor of Science degree in chemistry, summa cum laude, from Fairleigh Dickinson University, and a Doctor of Philosophy in cell biology from the SUNY Downstate Medical Center.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.